AKR1C3 expression level in 10 tumor tissue types.
tumor, SCC squamous cell carcinoma, Tumor, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell carcinoma, CRC colorectal carcinoma
TUMOR, TUMOR
AKR1C3 aldo-keto reductase family 1 member C3, CRC colorectal carcinoma, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell carcinoma, IHC immunohistochemistry, SCC squamous cell carcinoma. Tissue slides were considered evaluable if hematoxylin and eosin staining showed ≥100 viable tumor cells. AKR1C3 expression levels on consecutive tumor tissue slides were analyzed using the validated automated IHC assay on the Leica BOND-III platform (Leica Biosystems, Deer Park, Illinois, USA). Slides were incubated with anti-AKR1C3 antibody (Sigma-Millipore mouse monoclonal antibody, clone NP6.G6.A6, 1.2 µg/mL, 1:2000 dilution in BOND primary antibody diluent) or isotype control (Leica BOND ready-to-use negative control [mouse]) for 30 min. The Sigma-Millipore antibody has previously been validated against the following cell line controls: HCT 116 (negative control), genetically modified HCT 116 transfected with a derivative of plasmid F527-V5 EFα promoter to overexpress AKRIC3, Nalm (low endogenous expression), and TF1 (high endogenous expression) [Reagents from the BOND Polymer Refine DAB Kit were used to perform the following steps on the Leica BOND-III IHC platform. Tumor AKR1C3 expression was evaluated using the H-score system [